The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of S...

Full description

Bibliographic Details
Main Authors: Gang Ye, Joseph Gallant, Jian Zheng, Christopher Massey, Ke Shi, Wanbo Tai, Abby Odle, Molly Vickers, Jian Shang, Yushun Wan, Lanying Du, Hideki Aihara, Stanley Perlman, Aaron LeBeau, Fang Li
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2021-08-01
Series:eLife
Subjects:
COVID-19
single-chain antibody from camelids
spike protein receptor-binding domain
ACE2
crystal structures
virus neutralization
Online Access:https://elifesciences.org/articles/64815

Internet

https://elifesciences.org/articles/64815

Similar Items